Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure

Abstract

The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes. The data of the latest studies (EMPEROR reduced, VERTIS CV, SOLOIST-WHF, SCORED) are presented in more detail.

Keywords

• heart failure
• type 2 diabetes
• sodium-glucose co-transporter-2 inhibitor
• empagliflozin
• dapagliflozin
• canagliflozin
• ertugliflozin
• sotagliflozin